TY - JOUR
T1 - Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer
AU - Cheng, Ziyi
AU - Choi, Namhyun
AU - Wang, Rui
AU - Lee, Sangyeop
AU - Moon, Kyung Chul
AU - Yoon, Soo Young
AU - Chen, Lingxin
AU - Choo, Jaebum
N1 - Funding Information:
The National Research Foundation of Korea supported this work through grant numbers R11-2008-0061852 and K20904000004-12A0500-00410. The Nano Material Technology Development Program also supported this work, through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (grant number 2012035286). This work was also partially supported by the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare, Korea (HI16C2129). L.C. thanks the National Natural Science Foundation of China (21575159) for financial support.
Publisher Copyright:
© 2017 American Chemical Society.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/5/23
Y1 - 2017/5/23
N2 - Accurate analysis of specific biomarkers in clinical serum is essential for early diagnosis and treatment of cancer. Here, a surface-enhanced Raman scattering (SERS)-based immunoassay, using magnetic beads and SERS nano tags, was developed for the determination of free to total (f/t) prostate specific antigen (PSA) ratio to improve the diagnostic performance of prostate cancer. To assess the clinical applicability of the proposed method, SERS-based assays for the simultaneous detection of dual PSA markers, free PSA (f-PSA) and complexed PSA (c-PSA), were performed for clinical samples in the gray zone between 4.0 and 10.0 ng/mL. Our assay results for f/t PSA ratio showed a good linear correlation with those measured using the electrochemiluminescence (ECL) system installed in the clinical laboratory of the University Hospital. In addition, the simultaneous assay provided better precision than parallel assays for the detection of f-PSA and c-PSA in 13 clinical serum samples. Therefore, our SERS-based assay for simultaneous detection of dual PSA markers in clinical fluids has strong potential for application in the accurate diagnosis of prostate cancer.
AB - Accurate analysis of specific biomarkers in clinical serum is essential for early diagnosis and treatment of cancer. Here, a surface-enhanced Raman scattering (SERS)-based immunoassay, using magnetic beads and SERS nano tags, was developed for the determination of free to total (f/t) prostate specific antigen (PSA) ratio to improve the diagnostic performance of prostate cancer. To assess the clinical applicability of the proposed method, SERS-based assays for the simultaneous detection of dual PSA markers, free PSA (f-PSA) and complexed PSA (c-PSA), were performed for clinical samples in the gray zone between 4.0 and 10.0 ng/mL. Our assay results for f/t PSA ratio showed a good linear correlation with those measured using the electrochemiluminescence (ECL) system installed in the clinical laboratory of the University Hospital. In addition, the simultaneous assay provided better precision than parallel assays for the detection of f-PSA and c-PSA in 13 clinical serum samples. Therefore, our SERS-based assay for simultaneous detection of dual PSA markers in clinical fluids has strong potential for application in the accurate diagnosis of prostate cancer.
KW - SERS-based immunoassay
KW - free to total PSA ratio
KW - multiplex detection
KW - prostate cancer
KW - simultaneous detection
UR - http://www.scopus.com/inward/record.url?scp=85019918661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019918661&partnerID=8YFLogxK
U2 - 10.1021/acsnano.7b01536
DO - 10.1021/acsnano.7b01536
M3 - Article
C2 - 28441008
AN - SCOPUS:85019918661
VL - 11
SP - 4926
EP - 4933
JO - ACS Nano
JF - ACS Nano
SN - 1936-0851
IS - 5
ER -
